TFA Therapeutics RAJAF Income Statement (2020-2025)

OTC RAJAF
$9.18 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT
Reported Financials

TFA Therapeutics Quarterly Income Statement

Periods 7 quarters
Latest Dec 2025

TFA Therapeutics income statement data for the quarter ended Dec 2025. This income statement covers 7 quarters of results from Dec 2020 through Dec 2025, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2020 Dec2021 Dec2022 Sep2023 Dec2023 Dec2024 Dec2025
Revenue & cost
Revenue 0.13M0.01M0.01M0.32M
Cost of RevenueCost of Rev 0.04M0.03M
Gross Profit 0.09M-0.18M-0.11M0.28M
Operating items
Depreciation & Amortization - TotalDep. & Amort. (Tot) 112.00
Research & DevelopmentR&D 0.01M
Selling, General & AdministrativeSG&A 0.08M0.08M0.35M
Other Operating ExpensesOther Opex -460.00-0.00M-0.19M
Operating ExpensesOpex 0.09M0.08M0.16M
Operating IncomeOp. Inc 0.01M-0.04M0.12M
EBIT 0.01M-0.04M0.12M
Non-operating items
Non Operating Interest Expenses 0.02M
Interest & Investment IncomeInt & Inv Inc 7.00
Other Non Operating IncomeOther Non Op Inc. 11.00-0.03M-0.02M
Non Operating IncomeNon Op. Inc. -0.02M-0.01M-0.08M-0.04M
Net income details
EBT -0.01M-0.04M0.08M
Tax ProvisionsTaxes 0.00M
Profit After TaxPAT -0.01M-1.33M0.67M
Income from Continuing OperationsIncome (Continuing) -0.01M-0.04M0.08M
Income from Discontinued OperationsIncome (Discontinued) -0.37M-0.30M-0.03M
Consolidated Net IncomeConsol Net Inc. -0.01M-0.37M-0.34M0.06M
Income towards Parent CompanyParent Net Inc -0.01M-0.37M-0.34M0.06M
Net Income towards Common StockholdersNet Income -0.01M-0.37M-0.34M0.06M
Additional items
EPS (Basic) 0.000.000.000.00
EPS (Diluted) 0.000.000.000.00
Shares Outstanding 100.00M100.00M104.42M104.42M111.12M111.12M111.12M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 100.00M100.00M104.42M104.42M111.12M111.12M111.12M
Shares Outstanding (Entity)Shares Outstanding (Entity.) 111.12M111.12M111.12M111.12M111.12M111.12M
EBITDA 0.01M-0.04M0.12M
Interest ExpensesInt Expense 0.02M
Tax Rate -16.84%